Shehab_2024_Sci.Rep_14_15436

Reference

Title : Pharmacokinetic and molecular docking studies to pyrimidine drug using Mn(3)O(4) nanoparticles to explore potential anti-Alzheimer activity - Shehab_2024_Sci.Rep_14_15436
Author(s) : Shehab WS , Haikal HA , Elsayed DA , El-Farargy AF , El-Gazzar ABA , El-Bassyouni GT , Mousa SM
Ref : Sci Rep , 14 :15436 , 2024
Abstract :

Alzheimer disease (AD) is the cause of dementia and accounts for 60-80% cases. Tumor Necrosis Factor-alpha (TNF-alpha) is a multifunctional cytokine that provides resistance to infections, inflammation, and cancer. It developed as a prospective therapeutic target against multiple autoimmune and inflammatory disorders. Cholinergic insufficiency is linked to Alzheimer's disease, and several cholinesterase inhibitors have been created to treat it, including naturally produced inhibitors, synthetic analogs, and hybrids. In the current study, we tried to prepared compounds may also support the discovery and development of novel therapeutic and preventative drugs for Alzheimer's using manganese tetroxide nanoparticles (Mn(3)O(4)-NPs) as a catalyst to generate compounds with excellent reaction conditions. The Biginelli synthesis yields 4-(4-cyanophenyl)-6-oxo-2-thioxohexahydropyrimidine-5-carbonitrile when the 4-cyanobenzaldehyde, ethyl cyanoacetate, and thiourea were coupled with Mn(3)O(4)-NPs to produce compound 1. This multi-component method is non-toxic, safe, and environmentally friendly. The new approach reduced the amount of chemicals used and preserved time. Compound 1 underwent reactions with methyl iodide, acrylonitrile, chloroacetone, ethyl chloroacetate, and chloroacetic acid/benzaldehyde, each of the synthetized compounds was docked with TNF-alpha converting enzyme. These compounds may also support the discovery and development of novel therapeutic and preventative drugs for Alzheimer's disease. The majority of the produced compounds demonstrated pharmacokinetic features, making them potentially attractive therapeutic candidates for Alzheimer's disease treatment.

PubMedSearch : Shehab_2024_Sci.Rep_14_15436
PubMedID: 38965280

Related information

Citations formats

Shehab WS, Haikal HA, Elsayed DA, El-Farargy AF, El-Gazzar ABA, El-Bassyouni GT, Mousa SM (2024)
Pharmacokinetic and molecular docking studies to pyrimidine drug using Mn(3)O(4) nanoparticles to explore potential anti-Alzheimer activity
Sci Rep 14 :15436

Shehab WS, Haikal HA, Elsayed DA, El-Farargy AF, El-Gazzar ABA, El-Bassyouni GT, Mousa SM (2024)
Sci Rep 14 :15436